Compare Nike Inc (NKE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Sana Biotechnology Inc — how do they compare? Nike Inc trades at $34.65 (market cap $51.60B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Nike Inc is far larger — about 61.7× Sana Biotechnology Inc's market cap, and Nike Inc pays a 4.72% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Sana Biotechnology Inc for 23 Days on average.
| NKE | SANA | |
|---|---|---|
Market Cap | $51.60B | $836.71M |
Volume | 43,506,062 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $5.92 |
52-Week Low | $33.87 | $2.68 |
Typical Hold Time | 155 Days | 23 Days |
Enterprise Value | $54.30B | $749.96M |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike's stock trades at $34.36, down 0.72% with a bearish technical outlook. The company reported $46.31B in revenue for 2025 with a 6.74% net margin, though earnings have beaten expectations in recent quarters. Analyst consensus remains positive with a $36.98 price target, while recent news highlights challenges in China and inventory management.
Nike faces near-term headwinds from slowing revenue growth and margin pressure, but strong brand positioning and consistent earnings beats provide upside potential. Key risks include consumer demand weakness and competitive pressures, while institutional sentiment remains cautiously optimistic for a turnaround.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
